锂盐对比维拉帕米治疗躁狂症的优势：一项随机、对照、单盲试验
Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial.
作者信息
Walton S A, Berk M, Brook S
机构信息
Department of Psychiatry, University of the Witwatersrand Medical School, Johannesburg, South Africa.
出版信息
J Clin Psychiatry. 1996 Nov;57(11):543-6. doi: 10.4088/jcp.v57n1108.
BACKGROUND
Both case reports and small controlled studies suggest the efficacy of verapamil in the treatment of mania.
METHOD
Forty patients with DSM-IV mania were studied in a 28-day randomized, controlled, single-blind trial of either lithium or verapamil.
RESULTS
The patients receiving lithium showed a significant improvement on all rating scales (Brief Psychiatric Rating Scale [BPRS], Mania Rating Scale [MRS], Global Assessment of Functioning [GAF], and Clinical Global Impression [CGI]) compared with those receiving verapamil. The mean MRS score at Day 28 in the lithium group was significantly lower than that in the verapamil group (17.47 vs. 24.43, respectively; F = 6.17, df = 1, p = .018). A similar pattern was seen with the BPRS (12.68 vs. 20.57; F = 10.69, df = 1, p = .002), CGI (2.31 vs. 3.33; F = 6.05, df = 1, p = .019), and GAF (43.52 vs. 52.31; F = 4.36, df = 1, p = .044) (ANCOVA).
CONCLUSION
This study suggests that lithium is superior to verapamil in the management of acute mania.
背景
病例报告和小型对照研究均表明维拉帕米在治疗躁狂症方面具有疗效。
方法
对40例符合《精神疾病诊断与统计手册》第四版（DSM-IV）标准的躁狂症患者进行了一项为期28天的随机、对照、单盲试验，比较锂盐和维拉帕米的疗效。
结果
与接受维拉帕米治疗的患者相比，接受锂盐治疗的患者在所有评定量表（简明精神病评定量表[BPRS]、躁狂评定量表[MRS]、总体功能评定量表[GAF]和临床总体印象量表[CGI]）上均有显著改善。锂盐组在第28天的平均MRS评分显著低于维拉帕米组（分别为17.47和24.43；F = 6.17，自由度 = 1，p = .018）。BPRS（12.68对20.57；F = 10.69，自由度 = 1，p = .002）、CGI（2.31对3.33；F = 6.05，自由度 = 1，p = .019）和GAF（43.52对52.31；F = 4.36，自由度 = 1，p = .044）也呈现出类似的模式（协方差分析）。
结论
本研究表明，在急性躁狂症的治疗中，锂盐优于维拉帕米。
Zotero 插件